Abstract
In this prospective, single-centre, slightly underpowered, double-blind randomised controlled trial (RCT) with intention-to-treat analysis, use of moderate-dose hydrocortisone in etomidate-related adrenal insufficiency was not shown to reduce the proportion of patients with a cardiovascular Sequential Organ Failure Assessment (SOFA) score of 3 or 4.
Level of evidence: 2B (CEBM, low quality RCT)